Revolution Medicines (RVMD) Projected to Post Earnings on Monday

Revolution Medicines (NASDAQ:RVMD - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($1.01) per share and revenue of $0.35 million for the quarter.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD traded down $0.08 during mid-day trading on Thursday, hitting $42.26. 793,968 shares of the company traded hands, compared to its average volume of 1,276,705. The firm's 50 day simple moving average is $42.62 and its 200 day simple moving average is $46.28. The firm has a market cap of $7.11 billion, a P/E ratio of -11.77 and a beta of 1.45. Revolution Medicines has a 52-week low of $28.43 and a 52-week high of $62.40.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wedbush reissued an "outperform" rating and set a $70.00 target price on shares of Revolution Medicines in a research report on Monday, December 2nd. Piper Sandler lifted their price target on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Guggenheim upped their price objective on shares of Revolution Medicines from $82.00 to $87.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. UBS Group raised their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, Oppenheimer boosted their price target on Revolution Medicines from $55.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, October 28th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $66.25.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, Director Thilo Schroeder bought 1,304,347 shares of the business's stock in a transaction on Thursday, December 5th. The shares were purchased at an average price of $46.00 per share, with a total value of $59,999,962.00. Following the purchase, the director now directly owns 2,096,612 shares of the company's stock, valued at approximately $96,444,152. The trade was a 164.64 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark A. Goldsmith sold 11,714 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.40, for a total value of $531,815.60. Following the completion of the transaction, the insider now directly owns 325,056 shares of the company's stock, valued at approximately $14,757,542.40. The trade was a 3.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,678 shares of company stock valued at $847,981 in the last ninety days. Company insiders own 8.00% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.